This Breast SPORE Advocacy Core (BSAC) was one of the first organized patient advocacy initiatives formally connected to an NCI-funded research program in the US. The Core is currently comprised of a nucleus of 11 team members, who connect with over 100 breast cancer advocates and survivors on local and national levels. These individuals support Bay Area Breast Cancer SPORE projects and cores by infusing relevant patient experiences into the SPORE, by addressing recurrent barriers to translational research, and by networking with various organizations throughout the Bay Area and nationally. The Advocacy Core has become an even more service-focused core in order to provide a mutually rewarding experience for both advocates and SPORE investigators. These services are primarily focused around research support, education/outreach, tissue acquisition/core issues, clinical trials, and policy issues: Research Support is provided to Project Investigators to further the translational goals of the SPORE by incorporating advocate involvement and collaboration. Education/Outreach services consist of forums that promote communication, education, and awareness between researchers, patient advocates and the public to make SPORE projects applicable to people with cancer. Clinical Trial services include participation in protocol and informed consent development for UCSF investigator-initiated clinical studies and SPORE projects. Work done by advocates on Tissue usage and acquisition help facilitate increased specimen collection and provide input and review of the use of the tissue collected from breast cancer patients. The Advocacy Core also continues its Policy Issues work by planning and promoting a knowledge base on emerging policy and ethical issues involved in translational research. Strategic Planning involves direct interactions with other SPORE programs, interSPORE activities, and engagement with other advocacy groups.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058207-18
Application #
8377733
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
2013-11-30
Budget Start
2012-01-20
Budget End
2012-11-30
Support Year
18
Fiscal Year
2012
Total Cost
$106,062
Indirect Cost
$69,203
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Campbell, Jeffrey I; Yau, Christina; Krass, Polina et al. (2017) Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 165:181-191
Bolan, Patrick J; Kim, Eunhee; Herman, Benjamin A et al. (2017) MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. J Magn Reson Imaging 46:290-302
Campbell, Michael J; Baehner, Frederick; O'Meara, Tess et al. (2017) Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat 161:17-28
Olow, Aleksandra; Chen, Zhongzhong; Niedner, R Hannes et al. (2016) An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer. Cancer Res 76:1733-45
Hu, Zhi; Mao, Jian-Hua; Curtis, Christina et al. (2016) Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast Cancer Res 18:70
Takai, Ken; Le, Annie; Weaver, Valerie M et al. (2016) Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget 7:82889-82901
Malkov, Serghei; Shepherd, John A; Scott, Christopher G et al. (2016) Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status. Breast Cancer Res 18:122
Gu, Shenda; Hu, Zhi; Ngamcherdtrakul, Worapol et al. (2016) Therapeutic siRNA for drug-resistant HER2-positive breast cancer. Oncotarget 7:14727-41
Molinaro, Annette M; Sison, Jennette D; Ljung, Britt-Marie et al. (2016) Risk prediction for local versus regional/metastatic tumors after initial ductal carcinoma in situ diagnosis treated by lumpectomy. Breast Cancer Res Treat 157:351-361
Drake, Christopher R; Estévez-Salmerón, Luis; Gascard, Philippe et al. (2015) Towards aspirin-inspired self-immolating molecules which target the cyclooxygenases. Org Biomol Chem 13:11078-86

Showing the most recent 10 out of 337 publications